Lucentis Ranibizumab - .5mg Single-Use Vial for Intrvitreal Injection

Description (Brief):

(From box) For intravitreal injection only.

Description (Brief)

(From insert) LUCENTIS is indicated for the treatment of patients with:

Description (Brief)

--NEovascular (Wet) Age-Related Macular Degeneration

Description (Brief)

--Macular Edema Followign Retinal Vein Occlusion

Description (Brief)

--Diabetic Macular Edema

Date Made: ca 2013Product Expiration Date: 2015-07

Maker: Genentech, Inc.

Location: Currently not on view

Place Made: United States: California, South San Francisco

See more items in: Medicine and Science: Medicine, Health & Medicine, The Antibody Initiative, Antibody Initiative: Monoclonal Antibodies

Exhibition:

Exhibition Location:

Credit Line: Gift of Genentech, Inc.

Data Source: National Museum of American History

Id Number: 2013.0069.07Catalog Number: 2013.0069.07Accession Number: 2013.0069

Object Name: pharmaceuticalbiological

Physical Description: glass (overall material)plastic (overall material)metal (overall material)paper (overall material)cardboard (overall material)Ranibizumab, 0.5 mg (overall ingredient)Measurements: overall: 3/4 in x 2 5/8 in x 3 1/2 in; 1.905 cm x 6.6675 cm x 8.89 cmbottle of lucentis: 1 1/2 in x 5/8 in; 3.81 cm x 1.5875 cmfilter needle: 3/4 in x 3 5/8 in x 1/4 in; 1.905 cm x 9.2075 cm x .635 cmprecisionglide needle: 3/4 in x 3 3/16 in x 1/4 in; 1.905 cm x 8.09625 cm x .635 cmoverall: 3 1/2 in x 2 1/2 in x 3/4 in; 8.89 cm x 6.35 cm x 1.905 cm

Guid: http://n2t.net/ark:/65665/ng49ca746b3-0e3d-704b-e053-15f76fa0b4fa

Record Id: nmah_1445181

Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.

If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.